NHG-Richtlijnen
NHG-Standaard
M42
3.1
december 2022
april 2024
U. Urinewegen

Richtlijnen diagnostiek

Naar Volledige tekst ›

Lichamelijk onderzoek

Naar Volledige tekst ›

Aanvullend onderzoek

Naar Volledige tekst ›

Evaluatie

Naar Volledige tekst ›

Richtlijnen beleid

Naar Volledige tekst ›

Voorlichting

Naar Volledige tekst ›

Niet-medicamenteuze behandeling

Naar Volledige tekst ›

Medicamenteuze behandeling

Naar Volledige tekst ›

Controles

Naar Volledige tekst ›

Consultatie en verwijzing

Naar Volledige tekst ›

Beleid bij acute urineretentie

Naar Volledige tekst ›

Belangrijkste wijzigingen

Naar Samenvatting ›

Kernboodschappen

Naar Samenvatting ›

Inleiding

Naar Samenvatting ›

Scope

Naar Samenvatting ›

Buiten de scope

Naar Samenvatting ›

Achtergronden

Naar Samenvatting ›

Begrippen

Naar Samenvatting ›

Aspecifieke mictieklachten

Naar Samenvatting ›

Urineretentie

Naar Samenvatting ›

Incontinentie

Naar Samenvatting ›

Epidemiologie

Naar Samenvatting ›

Pathofysiologie

Naar Samenvatting ›

Natuurlijk beloop en prognose

Naar Samenvatting ›

Richtlijnen diagnostiek

Naar Samenvatting ›

Anamnese

Naar Samenvatting ›

Lichamelijk onderzoek

Naar Samenvatting ›

Vragenlijst en plasdagboek

Naar Samenvatting ›

Aanvullend onderzoek

Naar Samenvatting ›

Evaluatie

Naar Samenvatting ›

Differentiaaldiagnose

Naar Samenvatting ›

Richtlijnen beleid

Naar Samenvatting ›

Voorlichting

Naar Samenvatting ›

Niet-medicamenteuze behandeling

Naar Samenvatting ›

Aspecifieke mictieklachten

Naar Samenvatting ›

Bij urgency en incontinentie als belangrijkste klacht

Naar Samenvatting ›

Bij nycturie als belangrijkste klacht

Naar Samenvatting ›

Medicamenteuze behandeling

Naar Samenvatting ›

Bij aspecifieke mictieklachten zonder urgency of nycturie als belangrijkste klacht

Naar Samenvatting ›
Alfablokkers
Naar Samenvatting ›
PDE-5-remmers (tadalafil)
Naar Samenvatting ›
Praktische toepassing
Naar Samenvatting ›
Niet-aanbevolen behandelingen bij aspecifieke mictieklachten
Naar Samenvatting ›
Combinatiebehandeling alfablokker met 5-alfa-reductaseremmer
Naar Samenvatting ›
Fytotherapie
Naar Samenvatting ›

Bij urgency (met en zonder incontinentie) als belangrijkste klacht

Naar Samenvatting ›
Muscarineantagonisten
Naar Samenvatting ›
Selectieve bèta-3-agonisten (mirabegron)
Naar Samenvatting ›
Combinatiebehandeling alfablokker en muscarineantagonist
Naar Samenvatting ›
Praktische toepassing
Naar Samenvatting ›

Bij nycturie als belangrijkste klacht

Naar Samenvatting ›
Muscarineantagonisten
Naar Samenvatting ›
Alfablokkers
Naar Samenvatting ›
Niet aanbevolen behandelingen bij nycturie
Naar Samenvatting ›
5-alfa-reductaseremmers
Naar Samenvatting ›
PDE-5-remmers
Naar Samenvatting ›
Mirabegron
Naar Samenvatting ›
Desmopressine
Naar Samenvatting ›
Lisdiuretica
Naar Samenvatting ›

Invasieve behandeling

Naar Samenvatting ›

Beleid bij acute urineretentie

Naar Samenvatting ›

Katheterisatie

Naar Samenvatting ›

Alfablokker na katheterisatie

Naar Samenvatting ›

Controles

Naar Samenvatting ›

Consultatie en verwijzing

Naar Samenvatting ›

Referenties

  1. Abrams P. New words for old: lower urinary extract symptoms for “prostatism”. Br Med J 1994;308:929.
  2. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology 2003;61:37-49.
  3. Blanker MH, Groeneveld FP, Bohnen AM, Bernsen RM, Prins A, Thomas S, et al. Voided volumes: normal values and relation to lower urinary tract symptoms in elderly men, a community-based study. Urology 2001a;57:1093-8.
  4. Bosch JL, Hop WC, Kirkels WJ, Schröder FH. The International Prostate Symptom Score in a community-based sample of men between 55 and 74 years of age: prevalence and correlation of symptoms with age, prostate volume, flow rate and residual urine volume. Br J Urol 1995;75:622-30.
  5. Van Venrooij GE, Boon TA. The value of symptom score, quality of life score, maximal urinary flow rate, residual volume and prostate size for the diagnosis of obstructive benign prostatic hyperplasia: a urodynamic analysis. J Urol 1996;155:2014-8.
  6. Eckhardt MD, Van Venrooij GE, Boon TA. Symptoms and quality of life versus age, prostate volume, and urodynamic parameters in 565 strictly selected men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Urology 2001;57:695-700.
  7. De La Rosette JJ, Witjes WP, Schafer W, Abrams P, Donovan JL, Peters TJ, et al. Relationships between lower urinary tract symptoms and bladder outlet obstruction: results from the ICS-”BPH” study. Neurourol Urodyn 1998;17:99-108.
  8. Ezz el Din K, Kiemeney LA, De Wildt MJ, Debruyne FM, De La Rosette JJ. Correlation between uroflowmetry, prostate volume, postvoid residue, and lower urinary tract symptoms as measured by the International Prostate Symptom Score. Urology 1996b;48:393-7.
  9. Van Venrooij GE, Boon TA, De Gier RP. International prostate symptom score and quality of life assessment versus urodynamic parameters in men with benign prostatic hyperplasia symptoms. J Urol 1995;153:1516-9.
  10. Witjes WP, Aarnink RG, Ezz-el-Din K, Wijkstra H, Debruyne EM, De La Rosette JJ. The correlation between prostate volume, transition zone volume, transition zone index and clinical and urodynamic investigations in patients with lower urinary tract symptoms. Br J Urol 1997;80:84-90.
  11. Botker-Rasmussen I, Bagi P, Jorgensen JB. Is bladder outlet obstruction normal in elderly men without lower urinary tract symptoms? Neurourol Urodyn 1999;18:545-51.
  12. Walker RM, Romano G, Davies AH, Theodorou NA, Springall RG, Carter SS. Pressure flow study data in a group of asymptomatic male control patients 45 years old or older. J Urol 2001;165:683-7.
  13. Chapple CR, Wein AJ, Abrams P, Dmochowski RR, Giuliano F, Kaplan SA, et al. Lower urinary tract symptoms revisited: a broader clinical perspective. Eur Urol 2008;54:563-9.
  14. Van Doorn B, Kok ET, Blanker MH, Martens EP, Bohnen AM, Bosch JL. The natural history and predictive factors of voided volume in older men: the Krimpen Study. J Urol 2011b;185:213-8.
  15. Guralnick ML, Grimsby G, Liss M, Szabo A, O’Connor RC. Objective differences between overactive bladder patients with and without urodynamically proven detrusor overactivity. Int Urogynecol J 2010;21:325-9.
  16. Coyne KS, Sexton CC, Vats V, Thompson C, Kopp ZS, Milsom I. National community prevalence of overactive bladder in the United States stratified by sex and age. Urology 2011;77:1081-7.
  17. Cheung WW, Blank W, Borawski D, Tran W, Bluth MH. Prevalence of overactive bladder, its under-diagnosis, and risk factors in a male urologic veterans population. Int J Med Sci 2010;7:391-4.
  18. Homma Y, Kakizaki H, Yamaguchi O, Yamanishi T, Nishizawa O, Yokoyama O, et al. Assessment of overactive bladder symptoms: comparison of 3-day bladder diary and the overactive bladder symptoms score. Urology 2011;77:60-4.
  19. Schlatmann TJ. Achtergronden van mictieklachten. In: Van Es JC, Keeman JN, De Leeuw PW, Zitman FG, editors. Medisch jaarboek 2001. Houten/Diegem: Bohn Stafleu Van Loghum, 2001: 191-6.
  20. Kaplan SA, Wein AJ, Staskin DR, Roehrborn CG, Steers WD. Urinary retention and post-void residual urine in men: separating truth from tradition. J Urol 2008;180:47-54.
  21. Fitzpatrick JM, Desgrandchamps F, Adjali K, Gomez GL, Hong SJ, El KS, et al. Management of acute urinary retention: a worldwide survey of 6074 men with benign prostatic hyperplasia. BJU Int 2012;109:88-95.
  22. Stoffel JT. Non-neurogenic Chronic Urinary Retention: what are we treating? Curr Urol Rep 2017;18:74.
  23. NVU. Mannelijke niet-neurogene LUTS (2017). Nederlandse Vereniging voor Urologie.
  24. Martin J, Chandler W, Speakman M. Investigating chronic urinary retention. BMJ 2019;366:l4590.
  25. NVU. Bacteriële urineweginfecties bij adolescenten en volwassenen. Etiologie, diagnostiek, behandeling en profylaxe (2009). Nederlandse Vereniging voor Urologie.
  26. Malde S, Cartwright R, Tikkinen KAO. What's New in Epidemiology? Eur Urol Focus 2018;4:11-3.
  27. Pesonen JS, Cartwright R, Mangera A, Santti H, Griebling TL, Pryalukhin AE, et al. Incidence and remission of Nocturia: a systematic review and meta-analysis. Eur Urol 2016;70:372-81.
  28. Tikkinen KA, Johnson TM, Tammela TL, Sintonen H, Haukka J, Huhtala H, et al. Nocturia frequency, bother, and quality of life: how often is too often? A population-based study in Finland. Eur Urol 2010;57:488-96.
  29. Blanker MH, Bernsen RM, Bosch JL, Thomas S, Groeneveld FP, Prins A, et al. Normal values and determinants of circadian urine production in older men: a population based study. J Urol 2002a;168:1453-7.
  30. Van Doorn B, Blanker MH, Kok ET, Westers P, Bosch JL. Prevalence, incidence and resolution of nocturnal polyuria in a longitudinal community-based study in older men: the Krimpen study. Eur Urol 2013;63:542-7.
  31. Blanker MH, Groeneveld FP, Prins A, Bernsen RM, Bohnen AM, Bosch JL. Strong effects of definition and nonresponse bias on prevalence rates of clinical benign prostatic hyperplasia: the Krimpen study of male urogenital tract problems and general health status. BJU Int 2000a;85:665-71.
  32. Wolters R, Wensing M, Van Weel C, Van der Wilt GJ, Grol RP. Lower urinary tract symptoms: social influence is more important than symptoms in seeking medical care. BJU Int 2002;90:655-61.
  33. Sonke GS, Kolman D, De La Rosette JJ, Donkers LHC, Boyle P, Kiemeney LALM. Prevalentie van lagere-urinewegsymptomen bij mannen en de invloed op hun kwaliteit van leven: Het Boxmeer-onderzoek. Ned Tijdschr Geneeskd 2000;144:2558-63.
  34. Wolfs GG, Knottnerus JA, Van der Horst FG, Visser AP, Janknegt RA. Determinants of doctor consultation for micturition problems in an elderly male population. Eur Urol 1998;33:1-10.
  35. Kok ET, Bohnen AM, Groeneveld FP, Busschbach JJ, Blanker MH, Bosch JL. Changes in disease specific and generic quality of life related to changes in lower urinary tract symptoms: the Krimpen study. J Urol 2005;174:1055-8.
  36. Sarma AV, Jacobsen SJ, Girman CJ, Jacobson DJ, Roberts RO, Rhodes T, et al. Concomitant longitudinal changes in frequency of and bother from lower urinary tract symptoms in community dwelling men. J Urol 2002;168:1446-52.
  37. Blanker MH, Alma HJ, Devji TS, Roelofs M, Steffens MG, Van der Worp H. Determining the minimal important differences in the International Prostate Symptom Score and Overactive Bladder Questionnaire: results from an observational cohort study in Dutch primary care. BMJ Open 2019;9:e032795.
  38. Barry MJ, Williford WO, Chang Y, Machi M, Jones KM, Walker-Corkery E, et al. Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients. J Urol 1995;154:1770-4.
  39. Parsons JK, Wilt TJ, Wang PY, Barrett-Connor E, Bauer DC, Marshall LM. Progression of lower urinary tract symptoms in older men: a community based study. J Urol 2010;183:1915-20.
  40. Thom D. Variation in estimates of urinary incontinence prevalence in the community: effects of differences in definition, population characteristics, and study type. J Am Geriatr Soc 1998;46:473-80.
  41. ICS. Incontinence. 4th ed. Parijs: International Consultation on Incontinence, 2009.
  42. Herzog AR, Diokno AC, Brown MB, Normolle DP, Brock BM. Two-year incidence, remission, and change patterns of urinary incontinence in noninstitutionalized older adults. J Gerontol 1990;45:M67-M74.
  43. McGrother CW, Donaldson MM, Shaw C, Matthews RJ, Hayward TA, Dallosso HM, et al. Storage symptoms of the bladder: prevalence, incidence and need for services in the UK. BJU Int 2004;93:763-9.
  44. Boyle P, Robertson C, Mazzetta C, Keech M, Hobbs FD, Fourcade R, et al. The prevalence of lower urinary tract symptoms in men and women in four centres. The UrEpik study. BJU Int 2003a;92:409-14.
  45. Boyle P, Robertson C, Mazzetta C, Keech M, Hobbs FD, Fourcade R, et al. The prevalence of male urinary incontinence in four centres: the UREPIK study. BJU Int 2003b;92:943-7.
  46. Kupelian V, Wei JT, O‘Leary MP, Kusek JW, Litman HJ, Link CL et al. Prevalence of lower urinary tract symptoms and effect on quality of life in a racially and ethnically diverse random sample: the Boston Area Community Health (BACH) Survey. Arch Intern Med 2006;166:2381-7.
  47. Roberts RO, Rhodes T, Panser LA, Girman CJ, Chute CG, Oesterling JE, et al. Natural history of prostatism: worry and embarrassment from urinary symptoms and health care-seeking behavior. Urology 1994;43:621-8.
  48. Andersson SO, RashidKhani B, Karlberg L, Wolk A, Johansson JE. Prevalence of lower urinary tract symptoms in men aged 45-79 years: a population-based study of 40 000 Swedish men. BJU Int 2004;94:327-31.
  49. Seim A, Hoyo C, Ostbye T, Vatten L. The prevalence and correlates of urinary tract symptoms in Norwegian men: the HUNT study. BJU Int 2005;96:88-92.
  50. Joseph MA, Harlow SD, Wei JT, Sarma AV, Dunn RL, Taylor JM, et al. Risk factors for lower urinary tract symptoms in a population-based sample of African-American men. Am J Epidemiol 2003;157:906-14.
  51. Kristal AR, Arnold KB, Schenk JM, Neuhouser ML, Weiss N, Goodman P, et al. Race/ethnicity, obesity, health related behaviors and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. J Urol 2007;177:1395-400.
  52. Taylor J, McGrother CW, Harrison SC, Assassa PR. Lower urinary tract symptoms and related help-seeking behaviour in South Asian men living in the UK. BJU Int 2006;98:605-9.
  53. Wolfs GG, Knottnerus JA, Janknegt RA. Prevalence and detection of micturition problems among 2,734 elderly men. J Urol 1994;152:1467-70.
  54. Van de Lisdonk EH. Ervaren en aangeboden morbiditeit in de huisartspraktijk. Een onderzoek met dagboeken [dissertatie]. Nijmegen: Katholieke Universiteit, 1985.
  55. Van der Heide WK. Mannen met plasklachten in de huisartspraktijk [proefschrift]. Groningen: Rijksuniversiteit Groningen, 2006.
  56. Cunningham-Burley S, Allbutt H, Garraway WM, Lee AJ, Russell EB. Perceptions of urinary symptoms and health-care-seeking behaviour amongst men aged 40-79 years. Br J Gen Pract 1996;46:349-52.
  57. Sprangers MA, Schwartz CE. Integrating response shift into health-related quality of life research: a theoretical model. Soc Sci Med 1999;48:1507-15.
  58. Garraway WM, Russell EB, Lee RJ, Collins GN, McKelvie GB, Hehir M, et al. Impact of previously unrecognized benign prostatic hyperplasia on the daily activities of middle-aged and elderly men. Br J Gen Pract 1993;43:318-21.
  59. Sladden MJ, Hughes AM, Hirst GH, Ward JE. A community study of lower urinary tract symptoms in older men in Sydney, Australia. Aust N Z J Surg 2000;70:322-8.
  60. Lammers HA, Van Wijnhoven R, Teunissen TA, Harmsen S, Lagro-Janssen AL. Why do men suffering from LUTS seek primary medical care? A qualitative study. J Eval Clin Pract 2015;21:931-6.
  61. Teunissen TA, Lagro-Janssen AL. Sex differences in the use of absorbent (incontinence) pads in independently living elderly people: do men receive less care? Int J Clin Parct 2009;63:869-73.
  62. Van der Linden MW, Westert GP, De Bakker DH, Schellevis FG. Tweede Nationale Studie naar ziekten en verrichtingen in de huisartspraktijk. Kernrapport I: klachten en aandoeningen in de bevolking en in de huisartspraktijk. Utrecht/Bilthoven: NIVEL/RIVM, 2004.
  63. Van de Lisdonk EH, Van den Bosch WJHM, Lagro-Janssen ALM. Ziekten in de huisartspraktijk. 5e druk. Maarssen: Elsevier Gezondheidszorg, 2008.
  64. Buckley BS, Lapitan MC; Epidemiology Committee of the Fourth International Consultation on Incontinence. Prevalence of urinary incontinence in men, women, and children--current evidence: findings of the Fourth International Consultation on Incontinence. Urology 2010;76:265-70.
  65. Tubaro A, La Vecchia C; Uroscreening Study Group. The relation of lower urinary tract symptoms with life-style factors and objective measures of benign prostatic enlargement and obstruction: an Italian survey. Eur Urol 2004;45:767-72.
  66. Gass R. Benign prostatic hyperplasia: the opposite effects of alcohol and coffee intake. BJU Int 2002;90:649-54.
  67. Prezioso D, Catuogno C, Galassi P, D’Andrea G, Castello G, Pirritano D. Life-style in patients with LUTS suggestive of BPH. Eur Urol 2001;40 Suppl 1:9-12.
  68. Parsons JK, Im R. Alcohol consumption is associated with a decreased risk of benign prostatic hyperplasia. J Urol 2009;182:1463-8.
  69. Matzkin H, Soloway MS. Cigarette smoking: a review of possible associations with benign prostatic hyperplasia and prostate cancer. Prostate 1993;22:277-90.
  70. Laven BA, Orsini N, Andersson SO, Johansson JE, Gerber GS, Wolk A. Birth weight, abdominal obesity and the risk of lower urinary tract symptoms in a population based study of Swedish men. J Urol 2008;179:1891-5.
  71. Parsons JK, Carter HB, Partin AW, Windham BG, Metter EJ, Ferrucci L, et al. Metabolic factors associated with benign prostatic hyperplasia. J Clin Endocrinol Metab 2006;91:2562-8.
  72. Kok ET, Bohnen AM, Bosch JL, Thomas S, Groeneveld FP, Patient’s quality of life and coping style influence general practitioner’s management in men with lower urinary tract symptoms: the Krimpen study. Qual Life Res 2006;15:1335-43.
  73. Noguchi N, Chan L, Cumming RG, Blyth FM, Handelsman DJ, Waite LM, et al. Natural history of non-neurogenic overactive bladder and urinary incontinence over 5 years in community-dwelling older men: the concord health and aging in men project. Neurourol Urodyn 2017;36:443-8.
  74. Sarma AV, Wei JT, Jacobson DJ, Dunn RL, Roberts RO, Girman CJ, et al. Comparison of lower urinary tract symptom severity and associated bother between community-dwelling black and white men: the Olmsted County Study of Urinary Symptoms and Health Status and the Flint Men’s Health Study. Urology 2003;61:1086-91.
  75. Van Doorn B, Blanker MH, Kok ET, Westers P, Bosch JL. Once nocturia, always nocturia? Natural history of nocturia in older men based on frequency-volume charts: the Krimpen study. J Urol 2011a;186:1956-61.
  76. Temml C, Brossner C, Schatzl G, Ponholzer A, Knoepp L, Madersbacher S. The natural history of lower urinary tract symptoms over five years. Eur Urol 2003;43:374-80.
  77. Blanker MH, Bohnen AM, Groeneveld FP, Bernsen RM, Prins A, Thomas S , et al. Correlates for erectile and ejaculatory dysfunction in older Dutch men: a community-based study. J Am Geriatr Soc 2001b;49:436-42.
  78. Blanker MH, Bohnen AM, Groeneveld FP, Bernsen RM, Prins A, Bosch JL. Normal voiding patterns and determinants of increased diurnal and nocturnal voiding frequency in elderly men. J Urol 2000b;164:1201-5.
  79. Blanker MH, Prins J, Bohnen AM, Thomas S, Bosch JL. De waarde van het plasdagboek bij oudere mannen met plasklachten. Huisarts Wet 2003;46:243-7.
  80. Meigs JB, Barry MJ, Giovannucci E, Rimm EB, Stampfer MJ, Kawachi I. Incidence rates and risk factors for acute urinary retention: the health professionals followup study. J Urol 1999;162:376-82.
  81. Verhamme KM, Dieleman JP, Van Wijk MA, Bosch JL, Stricker BH, Sturkenboom MC. Low incidence of acute urinary retention in the general male population: the triumph project. Eur Urol 2005;47:494-8.
  82. Ponholzer A, Temml C, Obermayr RP, Rauchenwald M, Madersbacher S. The association between lower urinary tract symptoms and renal function in men: a cross-sectional and 5-year longitudinal analysis. J Urol 2006;175:1398-402.
  83. Hallan SI, Kwong D, Vikse BE, Stevens P. Use of a prostate symptom score to identify men at risk of future kidney failure: insights from the HUNT II Study. Am J Kidney Dis 2010;56:477-85.
  84. Hong SK, Lee ST, Jeong SJ, Byun SS, Hong YK, Park DS, et al. Chronic kidney disease among men with lower urinary tract symptoms due to benign prostatic hyperplasia. BJU Int 2010;105:1424-8.
  85. Cameron AP, Wiseman JB, Smith AR, Merion RM, Gillespie BW, Bradley CS, et al. Are three-day voiding diaries feasible and reliable? Results from the symptoms of lower urinary tract dysfunction research network (LURN) cohort. Neurourol Urodyn 2019;38:2185-93.
  86. Van Haarst, EP, Bosch JL, Heldeweg EA. The international prostate symptom score overestimates nocturia assessed by frequency-volume charts. J Urol 2012a;188:211-215.
  87. Averbeck MA, Madersbacher H. Constipation and LUTS - how do they affect each other? Int Braz J Urol 2011;37:16-28.
  88. Charach G, Greenstein A, Rabinovich P, Groskopf I, Weintraub M. Alleviating constipation in the elderly improves lower urinary tract symptoms. Gerontology 2001;47:72-6.
  89. CBS. Permanent Onderzoek LeefSituatie (POLS) (2011).
  90. Brown CT, O’Flynn E, Van der Meulen J, Newman S, Mundy AR, Emberton M. The fear of prostate cancer in men with lower urinary tract symptoms: should symptomatic men be screened? BJU Int 2003;91:30-2.
  91. Weatherall M, Harwood M. The accuracy of clinical assessment of bladder volume. Arch Phys Med Rehabil 2002;83:1300-2.
  92. Bosch JL, Bohnen AM, Groeneveld FP. Validity of digital rectal examination and serum prostate specific antigen in the estimation of prostate volume in community-based men aged 50 to 78 years: the Krimpen Study. Eur Urol 2004;46:753-9.
  93. NVU. Diagnostiek en behandeling van LUTS/BPH (2005). Nederlandse Vereniging voor Urologie.
  94. Lepor H, Machi G. Comparison of AUA symptom index in unselected males and females between fifty-five and seventy-nine years of age. Urology 1993;42:36-40.
  95. Chai TC, Belville WD, McGuire EJ, Nyquist L. Specificity of the American Urological Association voiding symptom index: comparison of unselected and selected samples of both sexes. J Urol 1993;150:1710-3.
  96. Abrams P, Klevmark B. Frequency volume charts: an indispensable part of lower urinary tract assessment. Scand J Urol Nephrol Suppl 1996;179:47-53.
  97. Gisolf KW, Van Venrooij GE, Eckhardt MD, Boon TA. Analysis and reliability of data from 24-hour frequency-volume charts in men with lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol 2000;38:45-52.
  98. Jones R, Latinovic R, Charlton J, Gulliford MC. Alarm symptoms in early diagnosis of cancer in primary care: cohort study using General Practice Research Database. BMJ 2007;334:1040.
  99. Jones R, Charlton J, Latinovic R, Gulliford MC. Alarm symptoms and identification of non-cancer diagnoses in primary care: cohort study. BMJ 2009;339:b3094.
  100. Ezz el Din K, Koch WF, De Wildt MJ, Debruyne FM, De La Rosette JJ. The predictive value of microscopic haematuria in patients with lower urinary tract symptoms and benign prostatic hyperplasia. Eur Urol 1996a;30:409-13.
  101. Chan ES, Ng CF, Hou SM, Yip SK. Using urine microscopy and cytology for early detection of bladder cancer in male patients with lower urinary tract symptoms. Int Urol Nephrol 2011;43:289-94.
  102. Khadra MH, Pickard RS, Charlton M, Powell PH, Neal DE. A prospective analysis of 1,930 patients with hematuria to evaluate current diagnostic practice. J Urol 2000;163:524-7.
  103. Boman H, Hedelin H, Holmang S. The results of routine evaluation of adult patients with haematuria analysed according to referral form information with 2-year follow-up. Scand J Urol Nephrol 2001;35:497-501.
  104. Rodgers M, Nixon J, Hempel S, Aho T, Kelly J. Neal D, et al. Diagnostic tests and algorithmes used in the investigation of haematuria: systematic reviews and economic evaluation. Health Technol Asess 2006;10:iii-iv,xi-259.
  105. NVKC. Richtlijn Eenduidige en accurate laboratoriumdiagnostiek bij hematurie (2021).
  106. NVU. Richtlijn Hematurie. (2010). Nederlandse Vereniging voor Urologie
  107. Lenis AT, Lec PM, Chamie K, Mshs MD. Bladder Cancer: a review. JAMA 2020;324:1980-91.
  108. Zackrisson B, Ulleryd P, Aus G, Lilja H, Sandberg T, Hugosson J. Evolution of free, complexed, and total serum prostate-specific antigen and their ratios during 1 year of follow-up of men with febrile urinary tract infection. Urology 2003;62:278-81.
  109. Bohnen AM, Groeneveld FP, Bosch JL. Serum prostate-specific antigen as a predictor of prostate volume in the community: the Krimpen study. Eur Urol 2007;51:1645-52.
  110. Stone BV, Shoag J, Halpern JA, Mittal S, Lewicki P, Golombos DM, et al. Prostate size, nocturia and the digital rectal examination: a cohort study of 30 500 men. BJU Int 2017;119:298-304.
  111. EAU. Guidelines on the management of male lower urinary tract symptoms (LUTS), incl. benign prostatic obstruction (BPO) (2012). 2012a.
  112. NICE. The management of lower urinary tract symptoms. NICE clinical guideline 97. Londen: National Clinical Guideline Centre, 2010. Ga naar bron
  113. Wasserman NF, Lapointe S, Eckmann DR, Rosel PR. Assessment of prostatism: role of intravenous urography. Radiology 1987;165:831-5.
  114. Patel NS, Blick C, Kumar PV, Malone PR. The diagnostic value of abdominal ultrasound, urine cytology and prostate-specific antigen testing in the lower urinary tract symptoms clinic. Int J Clin Pract 2009;63:1734-8.
  115. D'Silva KA, Dahm P, Wong CL. Does this man with lower urinary tract symptoms have bladder outlet obstruction? The rational clinical examination: a systematic review. JAMA 2014;312:535-42.
  116. Lai KY, Chan WK, Ho WF, Leung CS, Li YK. Application of bladder scan in ambulatory management protocol for acute urinary retention with presumed diagnosis of benign prostatic hypertrophy. Hong Kong J Emerg Med 2014;5:300-7.
  117. Nixon G, Blattner K, Muirhead J, Kerse N. Rural point-of-care ultrasound of the kidney and bladder: quality and effect on patient management. J Prim Health Care 2018;10:324-30.
  118. Krieger JN, Nyberg L, Jr., Nickel JC. NIH consensus definition and classification of prostatitis. JAMA 1999;282:236-7.
  119. Mundy AR, Andrich DE. Urethral strictures. BJU Int 2011;107:6-26.
  120. Wolters R, Wensing M, Van Weel C, Grol R. The effect of a distance-learning programme on patient self-management of Lower Urinary Tract Symptoms (LUTS) in general practice: a randomised controlled trial. Eur Urol 2004;46:95-101.
  121. Parsons JK, Kashefi C. Physical activity, benign prostatic hyperplasia, and lower urinary tract symptoms. Eur Urol 2008;53:1228-35.
  122. Parsons JK, Messer K, White M, Barrett-Connor E, Bauer DC, Marshall LM. Obesity increases and physical activity decreases lower urinary tract symptom risk in older men: the Osteoporotic Fractures in Men study. Eur Urol 2011;60:1173-80.
  123. Silva V, Grande AJ, Peccin MS. Physical activity for lower urinary tract symptoms secondary to benign prostatic obstruction. Cochrane Database Syst Rev 2019;4:CD012044.
  124. Albarqouni L, Sanders S, Clark J, Tikkinen KAO, Glasziou P. Self-management for men with lower urinary tract symptoms: a systematic review and meta-Analysis. Ann Fam Med 2021;19:157-67.
  125. Norg RJ. A general practitioner’s approach to lower urinary tract symptoms [PhD thesis], University Maastricht, 2008.
  126. Yazici CM, Turker P, Dogan C. Effect of voiding position on uroflowmetric parameters in healthy and obstructed male patients. Urol J 2014;10:1106-13.
  127. Alrabadi A, Al Demour S, Mansi H, AlHamss S, Al Omari L. Evaluation of voiding position on uroflowmetry parameters and post void residual urine in patients with benign prostatic hyperplasia and healthy men. Am J Mens Health 2020;14:1557988320938969.
  128. De Jong Y, Pinckaers JH, Ten Brinck RM, Lycklama à Nijeholt AA, Dekkers OM. Urinating standing versus sitting: position is of influence in men with prostate enlargement. A systematic review and meta-analysis. PLoS One 2014;9:e101320.
  129. Burgio KL, Goode PS, Johnson TM, Hammontree L, Ouslander JG, Markland AD, et al. Behavioral versus drug treatment for overactive bladder in men: the Male Overactive Bladder Treatment in Veterans (MOTIVE) Trial. J Am Geriatr Soc 2011;59:2209-16.
  130. Burgio KL, Kraus SR, Johnson TM, Markland AD, Vaughan CP, Li P, et al. Effectiveness of combined behavioral and drug therapy for overactive bladder symptoms in men: a randomized clinical trial. JAMA Intern Med 2020;180:411-9.
  131. Paterson J, Pinnock CB, Marshall VR. Pelvic floor exercises as a treatment for post-micturition dribble. Br J Urol 1997;79:892-7.
  132. Shafik A, Shafik IA. Overactive bladder inhibition in response to pelvic floor muscle exercises. World J Urol 2003;20:374-7.
  133. Dumoulin C, Hay-Smith J. Pelvic floor muscle training versus no treatment, or inactive control treatments, for urinary incontinence in women. Cochrane Database Syst Rev 2010;CD005654.
  134. Campbell SE, Glazener CM, Hunter KF, Cody JD, Moore KN. Conservative management for postprostatectomy urinary incontinence. Cochrane Database Syst Rev 2012;1:CD001843.
  135. Soda T, Masui K, Okuno H, Terai A, Ogawa O, Yoshimura K. Efficacy of nondrug lifestyle measures for the treatment of nocturia. J Urol 2010;184:1000-4.
  136. Weiss JP, Blaivas JG, Bliwise DL, Dmochowski RR, DuBeau CE, Lowe FC, et al. The evaluation and treatment of nocturia: a consensus statement. BJU Int 2011;108:6-21.
  137. Johnson TM, Markland AD, Goode PS, Vaughan CP, Colli JL, Ouslander JG, et al. Efficacy of adding behavioural treatment or antimuscarinic drug therapy to α-blocker therapy in men with nocturia. BJU Int 2013;112:100-8.
  138. Van Leeuwen JH, Castro R, Busse M, Bemelmans BL. The placebo effect in the pharmacologic treatment of patients with lower urinary tract symptoms. Eur Urol 2006;50:440-52.
  139. NICE. Evidence Update 11 of the NICE clinical guideline 97: The management of lower urinary tract symptoms in men. Londen: National Clinical Guideline Centre, 2012.
  140. Jung JH, Kim J, MacDonald R, Reddy B, Kim MH, Dahm P. Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia. Cochrane Database Syst Rev 2017:CD012615
  141. Oelke M, Giuliano F, Mirone V, Xu L, Cox D, Viktrup L. Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial. Eur Urol 2012;61:917-25.
  142. Van Kerrebroeck P, Chapple C, Drogendijk T, Klaver M, Sokol R, Speakman M, et al. Combination therapy with solifenacin and tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trial. Eur Urol 2013;64:1003-12.
  143. Chung JH, Oh CY, Kim JH, Ha US, Kim TH, Lee SH, et al. Efficacy and safety of tamsulosin 0.4 mg single pills for treatment of Asian patients with symptomatic benign prostatic hyperplasia with lower urinary tract symptoms: a randomized, double-blind, phase 3 trial. Curr Med Res Opin 2018;34:1793-1801.
  144. NICE. Clinical Guideline Update 97.1: The management of lower urinary tract symptoms in men. Londen: National Clinical Guideline Centre, 2015.
  145. Pattanaik S, Mavuduru RS, Panda A, Mathew JL, Agarwal MM, Hwang EC, et al. Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia. Cochrane Database Syst Rev 2018:CD010060.
  146. Zhang Z, Li H, Zhang X, Dai Y, Park HJ, Jiann BP, et al. Efficacy and safety of tadalafil 5 mg once-daily in Asian men with both lower urinary tract symptoms associated with benign prostatic hyperplasia and erectile dysfunction: A phase 3, randomized, double-blind, parallel, placebo- and tamsulosin-controlled study. Int J Urol 2019;26:192-200.
  147. Singh I, Tk A, Gupta S. Efficacy and safety of tadalafil vs tamsulosin in lower urinary tract symptoms (LUTS) as a result of benign prostate hyperplasia (BPH)-open label randomised controlled study. Int J Clin Pract 2020;74:e13530.
  148. Serati M, Andersson KE, Dmochowski R, Agrò EF, Heesakkers J, Iacovelli V, et al. Systematic Review of Combination Drug Therapy for Non-neurogenic Lower Urinary Tract Symptoms. Eur Urol 2019;75:129-168.
  149. Lepor H, Williford WO, Barry MJ, et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. N Engl J Med 1996;335:533.
  150. Debruyne FM, Jardin A, Colloi D, Resel L, Witjes WP, auche-Cavallier MC, et al. Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia. European ALFIN Study Group. Eur Urol 1998;34:169-75.
  151. Kirby RS. A randomized, double-blind crossover study of tamsulosin and controlled-release doxazosin in patients with benign prostatic hyperplasia. BJU Int 2003;91:41-4.
  152. McConnell JD, Roehrborn GC, Bautista OM, Andriole GL Jr, Dixon CM, Kusek JW, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003;349:2387-98.
  153. Roehrborn CG, Siami P, Barkin J, Damiao R, Major-Walker K, Nandy I et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol 2010;57:123-31.
  154. Tacklind J, Fink HA, MacDonald R, Rutks I, Wilt TJ. Finasteride for benign prostatic hyperplasia. Cochrane Database Syst Rev 2010;CD006015.
  155. Barry MJ, Meleth S, Lee JY, Kreder KJ, Avins AL, Nickel JC, et al. Effect of increasing doses of saw palmetto extract on lower urinary tract symptoms: a randomized trial. JAMA 2011;306:1344-51.
  156. Wilt TJ, N’Dow J. Benign prostatic hyperplasia. Part 1--diagnosis. BMJ 2008;336:146-9.
  157. Nabi G, Cody JD, Ellis G, Herbison P, Hay-Smith J. Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. Cochrane Database Syst Rev 2006;CD003781.
  158. Kaplan SA, Roehrborn CG, Rovner ES, Carlsson M, Bavendam T, Guan Z. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA 2006;296:2319-28.
  159. Rai BP, Cody JD, Alhasso A, Stewart L. Anticholinergic drugs versus non-drug active therapies for non-neurogenic overactive bladder syndrome in adults. Cochrane Database Syst Rev 2012:CD003193.
  160. Multidisciplinaire richtlijn (MDR) Polyfarmacie bij ouderen. Nederlands Huisartsen Genootschap, 2012.
  161. Gallagher P, Ryan C, Byrne S, Kennedy J, O’Mahony D. STOPP (Screening Tool of Older Person’s Prescriptions) and START (Screening Tool to Alert doctors to Right Treatment). Consensus validation. Int J Clin Pharmacol Ther 2008;46:72-83.
  162. Paquette A, Gou P, Tannenbaum C. Systematic review and meta-analysis: do clinical trials testing antimuscarinic agents for overactive bladder adequately measure central nervous system adverse events? J Am Geriatr Soc 2011;59:1332-9.
  163. De Nunzio C, Brucker B, Bschleipfer T, Cornu JN, Drake MJ, Fusco F, Gravas S, et al. Beyond Antimuscarinics: A Review of Pharmacological and Interventional Options for Overactive Bladder Management in Men. Eur Urol 2021;79:492-504.
  164. Wagg A, Staskin D, Engel E, Herschorn S, Kristy RM, Schermer CR. Efficacy, safety, and tolerability of mirabegron in patients aged ≥65yr with overactive bladder wet: a phase IV, double-blind, randomised, placebo-controlled study (PILLAR). Eur Urol 2020;77:211-20.
  165. Chapple CR, Cruz F, Cardozo L, Staskin D, Herschorn S, Choudhury N, et al. Safety and Efficacy of Mirabegron: Analysis of a Large Integrated Clinical Trial Database of Patients with Overactive Bladder Receiving Mirabegron, Antimuscarinics, or Placebo. Eur Urol 2020;77:119-128
  166. Tubaro A, Batista JE, Nitti VW, Herschorn S, Chapple CR, Blauwet MB, et al. Efficacy and safety of daily mirabegron 50 mg in male patients with overactive bladder: a critical analysis of five phase III studies. Ther Adv Urol 2017;9:137-154.
  167. Gacci M, Novara G, De Nunzio C, Tubaro A, Schiavina R, Brunocilla E, et al. Tolterodine extended release in the treatment of male OAB/storage LUTS: a systematic review. BMC Urol 2014;14:84.
  168. Chapple CR, Herschorn, S, Abrams P, Sun F, Brodsky M, Guan Z. Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers. Eur Urol 2009;56:543-41.
  169. Song Y, Chen G, Huang P, Hu C, Liu X. Effects of Tamsulosin Combined With Solifenacin on Lower Urinary Tract Symptoms: Evidence From a Systematic Review, Meta-Analysis, and Trial Sequential Analysis of Randomized Controlled Trials. Front Pharmacol 2020;11:763.
  170. Kaplan SA, McCammon K, Fincher R, Fakhoury A, He W. Safety and tolerability of solifenacin add-on therapy to alpha-blocker treated men with residual urgency and frequency. J Urol 2009;182:2825-30.
  171. Kaplan SA, Roehrborn CG, Gong J, Sun F, Guan Z. Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving α-blocker treatment for lower urinary tract symptoms. BJU Int 2012;109:1831-40.
  172. Singh I, Agarwal V, Garg G. 'Tamsulosin and Darifenacin' Versus 'Tamsulosin Monotherapy' for 'BPH with Accompanying Overactive Bladder'. J Clin Diagn Res 2015;9:PC08-11.
  173. Sakalis V, Sfiggas V, Vouros I, Salpiggidis G, Papathanasiou A, Apostolidis A. Combination of solifenacin with tamsulosin reduces prostate volume and vascularity as opposed to tamsulosin monotherapy in patients with benign prostate enlargement and overactive bladder symptoms: Results from a randomized pilot study. Int J Urol 2018;25:737-45.
  174. Elbadry M, Ali AI, Saleh E et al. The impact of adding solifenacin to tamsulosin therapy for treatment of storage lower urinary tract symptoms owing to benign prostatic hyperplasia. Afr J Urol 2020;26:84.
  175. Kaplan SA, Roehrborn CG, Dmochowski R, Rovner ES, Wang JT, Guan Z. Tolterodine extended release improves overactive bladder symptoms in men with overactive bladder and nocturia. Urology 2006;68:328-32.
  176. Madhuvrata PP, Singh M, Hasafa Z, Abdel-Fattah M. Anticholinergic drugs for adult neurogenic detrusor overactivity: a systematic review and meta-analysis. Eur Urol 2012; 62:816-30.
  177. Sakalis VI, Karavitakis M, Bedretdinova D, Bach T, Bosch JLHR, Gacci M, Gratzke C, Herrmann TR, Madersbacher S, Mamoulakis C, Tikkinen KAO, Gravas S, Drake MJ. Medical Treatment of Nocturia in Men with Lower Urinary Tract Symptoms: Systematic Review by the European Association of Urology Guidelines Panel for Male Lower Urinary Tract Symptoms. Eur Urol. 2017 Nov;72(5):757-769.
  178. Rackley R, Weiss JP, Rovner ES, Wang JT, Guan Z; 037 STUDY GROUP. Nighttime dosing with tolterodine reduces overactive bladder-related nocturnal micturitions in patients with overactive bladder and nocturia. Urology 2006;67:731-6.
  179. Weiss JP, Jumadilova Z, Johnson TM 2nd, Fitzgerald MP, Carlsson M, Martire DL, et al. Efficacy and safety of flexible dose fesoterodine in men and women with overactive bladder symptoms including nocturnal urinary urgency. J Urol 2013;189:1396-401.
  180. Djavan B, Milani S, Davies J, Bolodeoku J. The impact of tamsulosin oral controlled absorption system (OCAS) on nocturia and the quality of sleep: preliminary results of a pilot study. Eur Urol 2005;4:61-8.
  181. Eisenhardt A, Schneider T, Cruz F, Oelke M. Consistent and significant improvement of nighttime voiding frequency (nocturia) with silodosin in men with LUTS suggestive of BPH: pooled analysis of three randomized, placebo-controlled, double-blind phase III studies. World J Urol 2014;32:1119-25.
  182. Oelke M, Roehrborn CG, D'Ancona C, Wilson TH, Castro R, Manyak M. Nocturia improvement in the combination of Avodart(®) and tamsulosin (CombAT) study. World J Urol 2014;32:1133-40.
  183. Oelke M, Roehrborn CG, D'Ancona C, Wilson TH, Castro R, Manyak M. Impact of dutasteride on nocturia in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH): a pooled analysis of three phase III studies. World J Urol 2014;32:1141-7.
  184. Roehrborn CG, Boyle P, Nickel JC, Hoefner K, Andriole G; ARIA3001 ARIA3002 and ARIA3003 Study Investigators. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002;60:434-41.
  185. Johnson TM, Burrows PK, Kusek JW, Nyberg LM, Tenover JL, Lepor H, et al. Medical Therapy of Prostatic Symptoms Research Group. The effect of doxazosin, finasteride and combination therapy on nocturia in men with benign prostatic hyperplasia. J Urol 2007;178:2045-50.
  186. Johnson TM, Jones K, Williford WO, Kutner MH, Issa MM, Lepor H. Changes in nocturia from medical treatment of benign prostatic hyperplasia: secondary analysis of the Department of Veterans Affairs Cooperative Study Trial. J Urol 2003;170:145-8.
  187. Ko WJ, Han HH, Ham WS, Lee HW. Daily use of sildenafil 50mg at night effectively ameliorates nocturia in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: an exploratory multicenter, double-blind, randomized, placebo-controlled study. Aging Male 2017;20:81-8.
  188. Oelke M, Weiss JP, Mamoulakis C, Cox D, Ruff D, Viktrup L. Effects of tadalafil on nighttime voiding (nocturia) in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a post hoc analysis of pooled data from four randomized, placebo-controlled clinical studies. World J Urol 2014;32:1127-32.
  189. Porst H, Oelke M, Goldfischer ER, Cox D, Watts S, Dey D, et al. Efficacy and safety of tadalafil 5 mg once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: subgroup analyses of pooled data from 4 multinational, randomized, placebo-controlled clinical studies. Urology 2013;82:667-73.
  190. Batista JE, Kölbl H, Herschorn S, Rechberger T, Cambronero J, Halaska M, et al. The efficacy and safety of mirabegron compared with solifenacin in overactive bladder patients dissatisfied with previous antimuscarinic treatment due to lack of efficacy: results of a noninferiority, randomized, phase IIIb trial. Ther Adv Urol 2015;7:167-79
  191. Chapple CR, Dvorak V, Radziszewski P, Van Kerrebroeck P, Wyndaele JJ, Bosman B, et al. A phase II dose-ranging study of mirabegron in patients with overactive bladder. Int Urogynecol J. 2013;24:1447-58
  192. Han J, Jung JH, Bakker CJ, Ebell MH, Dahm P. Desmopressin for treating nocturia in men. Cochrane Database Syst Rev 2017:CD012059.
  193. Yamaguchi O, Juul KV, Falahati A, Yoshimura T, Imura F, Kitamura M. Efficacy and safety of 25 and 50 μg desmopressin orally disintegrating tablets in Japanese patients with nocturia due to nocturnal polyuria: Results from two phase 3 studies of a multicenter randomized double-blind placebo-controlled parallel-group development program. Low Urin Tract Symptoms 2020;12:8-19.
  194. Mattiasson A, Abrams P, Van Kerrebroeck P. Walter S, Weiss J. Efficacy of desmopressin in the treatment of nocturia: a double-blind placebo-controlled study in men. BJU Int 2002;89:855-62.
  195. Wang CJ, Lin YN, Huang SW, Chang CH. Low dose oral desmopressin for nocturnal polyuria with benign prostactic hyperplasia: a double-blind, placebo controlled randomized study. J Urol 2011;185:219-23.
  196. Weiss JP, Zinner NR, Klein BM, Nørgaard JP. Desmopressin orally disintegrating tablet effectively reduces nocturia: results of a randomized, double-blind, placebo-controlled trial. Neurourol Urodyn 2012;31:441-7.
  197. Yamaguchi O, Nishizawa O, Juul KV, Nørgaard JP. Gender difference in efficacy and dose response in Japanese patients with nocturia treated with four different doses of desmopressin orally disintegrating tablet in a randomized, placebo-controlled trial. BJU Int. 2013 Mar;111(3):474-84. doi: 10.1111/j.1464-410X.2012.11547.x. Epub 2012 Oct 9. PMID: 23046147.
  198. Serenity Pharmaceuticals. SER120 nasal spray advisory committee briefing document. Silver Spring: FDA, 2016. Ga naar bron
  199. Ceylan C, Ceylan T, Doluoglu OG, Yuksel S, Agras K. Comparing the effectiveness of intranasal desmopressin and doxazosin in men with nocturia: a pilot randomized clinical trial. Urol J. 2013;10:993-8.
  200. Pedersen PA, Johansen PB. Prophylactic treatment of adult nocturia with bumetanide. Br J Urol 1988;62:145-7.
  201. Reynard JM, Cannon A, Yang Q, Abrams P. A novel therapy for nocturnal polyuria: a double-blind randomized trial of frusemide against placebo. Br J Urol 1998;81:215-8.
  202. Graversen PH, Gasser TC, Wasson JH, Hinman F, Jr., Bruskewitz RC. Controversies about indications for transurethral resection of the prostate. J Urol 1989;141:475-81.
  203. AUA. Management of benign prostatic hyperplasia (BPH) (2010). American Urological Association.
  204. De La Rosette JJ, Alivizatos G, Madersbacher S, Rioja Sanz C, Nordling J, Emberton M. Guidelines on benign prostatic hyperplasia. Arnhem: European Association of Urology, 2002.
  205. Madersbacher S, Lackner J, Brossner C, Rohlich M, Stancik I, Willinger M, et al. Reoperation, myocardial infarction and mortality after transurethral and open prostatectomy: a nation-wide, long-term analysis of 23,123 cases. Eur Urol 2005;47:499-504.
  206. EAU. Guidelines on urinary incontinence (2012). 2012b.
  207. Armitage JN, Sibanda N, Cathcart PJ, Emberton M, Van der Meulen JH. Mortality in men admitted to hospital with acute urinary retention: database analysis. BMJ 2007;335:1199-202.
  208. Boettcher S, Brandt AS, Roth S, Mathers MJ, Lazica DA. Urinary retention: Benefit of gradual bladder decompression - myth or truth? A randomized controlled trial. Urol Int 2013;91:140-4.
  209. Yoon PD, Chalasani V, Woo HH. Systematic review and meta-analysis on management of acute urinary retention. Prostate Cancer Prostatic Dis 2015;18:297-302.
  210. Desgrandchamps F, De La Taille A, Doublet JD; RetenFrance Study Group. The management of acute urinary retention in France: a cross-sectional survey in 2618 men with benign prostatic hyperplasia. BJU Int 2006;97:727-33.
Keuzekaart - Problemen met plassen bij mannen zoals plas niet goed kunnen ophouden
Keuzekaart - Problemen met plassen bij mannen zoals zwakkere straal of nadruppelen
Urethrale katheter man; verwijderen en inbrengen
NHG-werkgroep:
Blanker MH, Bouthoorn SH, Greving JP, Klinkhamer S, Van der Does L, Van der Weele GM, Van Dijk N†, Weersma R, Wolters RJ
8 gerelateerde onderzoeken
E-mail